Insider transactions

Mathai Mammen

CIK 1421050 · EVP, Pharm, R&D · last filed 2024-06-13

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$26.06M
Companies
4
Total Filings
64
Lifetime Open-Market Net
-$4.70M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

THRX price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
THERAVANCE,INC.
901 GATEWAY BLVD.
SOUTH SAN FRANCISCO, CA 94080
Related Filers
Innoviva, Inc. — 50 joint filings, latest 2014-08-22
& Johnson Johnson — 3 joint filings, latest 2022-02-17
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
TXG Director 180,259 $77.13 $13.90M -$1.74M 7 2024-06-13
JNJ EVP, Pharm, R&D 45,300 $268.29 $12.15M $0 2 2022-02-17
Theravance Biopharma, Inc. (TBPH) Delisted SVP, Research & Development 288,111 $17.03 $4.91M $0 10 2016-03-17
Innoviva, Inc. (THRX) Delisted SVP, Research & Early Clin Dev 334,040 $4.06 $1.36M -$2.96M 44 2014-08-22

Recent Filings · Page 4 of 7

64 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2013-05-02 Innoviva, Inc. (THRX) Delisted Sell (S) −7,000 -$236.2K EDGAR
2013-02-22 Innoviva, Inc. (THRX) Delisted Mixed −12,002 -$265.5K EDGAR
2013-02-11 Innoviva, Inc. (THRX) Delisted Grant (A) +5,000 $0 EDGAR
2013-01-14 Innoviva, Inc. (THRX) Delisted Mixed +14,050 $45.0K EDGAR
2012-11-20 Innoviva, Inc. (THRX) Delisted Tax (F) −4,874 -$102.7K EDGAR
2012-11-16 Innoviva, Inc. (THRX) Delisted Exer (M) +5,161 $16.0K EDGAR
2012-11-06 Innoviva, Inc. (THRX) Delisted Sell (S) −7,000 -$150.2K EDGAR
2012-10-17 Innoviva, Inc. (THRX) Delisted Grant (A) +5,000 $0 EDGAR
2012-08-22 Innoviva, Inc. (THRX) Delisted Tax (F) −4,644 -$125.4K EDGAR
2012-08-15 Innoviva, Inc. (THRX) Delisted Sell (S) −25,000 -$643.5K EDGAR
Showing 31–40 of 64
Page 4 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.